|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00682955 |
|
Date of registration:
|
20/05/2008 |
|
Primary sponsor: |
|
|
Public title:
|
Comparing the Efficacy of Different Zinc Formulations in the Treatment of Diarrhea
Zinc |
|
Scientific title:
|
Comparing the Efficacy of Different Zinc Formulations in the Treatment of Acute Diarrhea Among Young Children at Hospital Based Setting in Pakistan |
|
Date of first enrolment:
|
August 2007 |
|
Target sample size:
|
300 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00682955 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Pakistan
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Children 6 months to 5 years of age
- Presented with passage of 3 or more loose or watery stools
- Caretakers are willing to let their child to participate in the study.
Exclusion Criteria:
- Failure to produce consent.
- Children with severe malnutrition or having chronic illness
Age minimum:
6 Months
Age maximum:
5 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Incidence of Abdominal Pain
|
|
Incidence of Acute Diarrhea
|
|
Intervention(s)
|
|
Drug: Zinc Sulphate
|
|
Primary Outcome(s)
|
|
Comparison of Efficacy of the two different Zinc Sulphate formulations
[Time Frame: 9 months]
|
|
Secondary Outcome(s)
|
|
Comparison of side effects of the two different Zinc Sulphate formulations used
[Time Frame: 9 months]
|
|
Secondary ID(s)
|
|
857-PED/ERC-07
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|